| Status | Study |
| Not yet recruiting |
Study Name: Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States Condition: Chronic Phase Chronic Myeloid Leukemia Date: 2017-01-31 |
| Not yet recruiting |
Study Name: A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Condition: Leukemia, Chronic Myeloid Date: 2016-11-22 Interventions: Drug: Nilotinib Nilotinib 300 |
| Completed |
Study Name: Pioglityazone and Imatinib for CML Patients Condition: Leukemia, Myeloid, Chronic-Phase Date: 2016-08-19 Interventions: Drug: Add-on therapy Pioglitazone therapy |
| Recruiting |
Study Name: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) Condition: Leukemia, Myeloid, Chronic-Phase Date: 2016-03-16 Interventions: Drug: Pioglitazone PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased t |
| Recruiting |
Study Name: A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Condition: Chronic Phase Chronic Myeloid Leukemia Date: 2015-08-13 Interventions: Drug: ponatinib 30 mg QD ponat |
| Recruiting |
Study Name: Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response Condition: Chronic Phase Chronic Myeloid Leukemia Date: 2013-08-29 Interventions: Drug: P1101 Other Name: PEG-Proline-Interferon alpha-2b |
| Active, not recruiting |
Study Name: Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells Condition: Leukemia, Myeloid, Chronic-Phase Date: 2013-05-14 Interventions: Drug: Nilotinib 300mg BID Nilotinib Other Name: Nilo |
| Active, not recruiting |
Study Name: Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response Condition: Chronic Phase Chronic Myeloid Leukemia Date: 2013-05-08 Interventions: Drug: Dasatinib Other Name: Sprycel |
| Completed |
Study Name: Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia Condition: Leukemia, Myeloid, Chronic-Phase Date: 2012-11-08 Interventions: Drug: Dasatinib + PegIFN |
| Recruiting |
Study Name: Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response Condition: Leukemia, Myeloid, Chronic-Phase Date: 2012-11-05 Interventions: Drug: Imatinib Mesylate Imatinib Mesylate LMC |